Abstract
Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic acid derivatives, for the potential oral treatment of hyperlipidemia. By March 2005, TAK-475 was undergoing phase III clinical trials in the US and Europe.
| Original language | English |
|---|---|
| Pages (from-to) | 850-856 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 7 |
| Issue number | 9 |
| Publication status | Published - 2006 |
